Tag:
CMO
Latest Headlines
Latest Headlines
Surya Pharmaceuticals closes 2 Indian API plants
While India is one of those countries where lots of companies are expanding drug manufacturing, it is not a guarantee that because you build, business will come.
Virtual is beautiful in biotech
I had the chance to moderate a panel at the BIO-Europe Spring meeting yesterday on new business models in biotech, with Torbjorn Bjerke, David Collier, Kevin Johnson, and Thomas Zioncheck joining the conversation.
Big quarterly loss whacks ex-Biogen chief's CMO amid transition
Wait until the second half of the fiscal year was Patheon ($PTI) CEO Jim Mullen's message after the contract drugmaker reported a $20.9 million loss.
GE Healthcare grabs Xcellerex to boost biomanufacturing prowess
GE Healthcare ($GE) is snatching up Xcellerex for an undisclosed price, another step in the company's plans to boost its position in biomanufacturing.
Analysts project red-hot Euro growth for CMO market
One of the big trends in pharma outsourcing in recent years has been a move to contracting out manufacturing services. Frost & Sullivan picked up on that trend in a recent market view, plotting...
It's 'T' time for contract manufacturers
As some CMOs have added development services to their offerings, they've differentiated themselves from their counterparts by adding the "D" from development: CDMO. Now, get ready to add a "T," for
Xoma cuts manufacturing to feed R&D
Berkeley, CA-based Xoma ($XOMA) is all but eliminating in-house manufacturing as it hunkers down into its area of expertise: discovery and development of monoclonal antibodies. The biotech said last
Catalent rethinks stainless for new bio plant
We checked in with Kent Payne, Catalent VP/GM for development and clinical services, after hearing about the CDMO's plans for a bioprocessing plant reliant on single-use technology. The Madison, WI,
Forecast: Pharma wants CMO consulting, regulatory support
For 2012, contract manufacturers should brace for an increase in requests for bioanalytical testing, consulting, high-potency compound and regulatory support services. But they should be able to
Doxil supplier's woes shine spotlight on CMO activity
Thanks to an ongoing shortage of Johnson & Johnson's ( $JNJ ) cancer drug Doxil , the unfolding drama at Ben Venue Laboratories has been on center stage. The FDA has repeatedly jumped on the
